# A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

> **NCT01303237** · — · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 88 (actual)

## Conditions studied

- Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
- LA SCCHN

## Interventions

- **DRUG:** Cetuximab + RT

## Key facts

- **NCT ID:** NCT01303237
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-28
- **Primary completion:** 2013-06-30
- **Final completion:** 2014-08-05
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** The study was discontinued due to slow recruitment and subjects not completing follow up period.
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303237, "A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01303237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*